statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cyclo Therapeutics reports FY results

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (Cyclo Therapeutics or the Company), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for...

Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol Cyclo for the Treatment of Alzheimers Disease

Company remains focused on generating shareholder value by advancing portfolio and identifying attractive opportunities for strategic investments Increased ownership in Day Three Labs to a majority...

Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results

Cyclo Therapeutics (NASDAQ:CYTH  Get Free Report) and Revolution Medicines (NASDAQ:RVMD  Get Free Report) are both medical companies, but which is the better investment? We will...

Contrasting Cyclo Therapeutics (NASDAQ:CYTH) and Revolution Medicines (NASDAQ:RVMD)

Acorda Therapeutics (NASDAQ:ACOR  Get Free Report) and Cyclo Therapeutics (NASDAQ:CYTH  Get Free Report) are both small-cap medical companies, but which is the better stock? We will...

Cyclo Therapeutics (NASDAQ:CYTH) vs. Acorda Therapeutics (NASDAQ:ACOR) Head-To-Head Comparison

Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimers Disease from the U.S. Patent and Trademark Office

Cyclo Therapeutics (CYTH) has released an update. Cyclo Therapeutics, Inc. has been informed by Nasdaq's Office of General Counsel that it has rect...

Cyclo Therapeutics Regains Compliance with Nasdaq Standards

Cyclo Therapeutics, Inc. (NASDAQ:CYTH  Get Free Report) was the target of a significant increase in short interest during the month of December. As of December 31st, there was short interest...

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Short Interest Up 83.3% in December

Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product pipeline include Trappsol Cyclo, which treats Neimann-Pick Type C disease and Alzheimer's disease. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.

Volume	16,858.00
52-Wk High	$2.57
52-Wk Low	$0.84

CYTH Cyclo Therapeutics Inc - Ordinary Shares - Class A

About

Feed

News

Fundamentals